US clinical research spending significantly down since Sunshine Act

US-based clinical research spending has dropped 32% in the first year-on-year comparison since Open Payments data started to be collected in the USA.

Research published in the August issue of Life Science Compliance Update showed that drug and device manufacturers reported around $1.5 billion in research payments from August through December 2013, the first reporting period under the Sunshine ACT. This fell to around $1 billion for the same period in 2014. Physicians, academic institutions and third-party research organizations received nearly $500 million less in research funding as a results.